NCT04142086View on ClinicalTrials.gov

Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

January 15, 2020

Primary Completion Date

June 24, 2021

Study Completion Date

June 24, 2021

Conditions
Yellow Fever (Healthy Volunteers)
Interventions
BIOLOGICAL

Yellow fever vaccine (produced on serum-free Vero cells), Dosage 1 vYF vaccine

Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous

BIOLOGICAL

Yellow fever vaccine (produced on serum-free Vero cells), Dosage 2 vYF vaccine

Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous

BIOLOGICAL

Yellow fever vaccine (produced on serum-free Vero cells), Dosage 3 vYF vaccine

Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous

BIOLOGICAL

Yellow fever vaccine

Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous

Trial Locations (1)

20910

Investigational Site Number 8400001, Silver Spring

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT04142086 - Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults | Biotech Hunter | Biotech Hunter